Back

A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension

30 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in primary care Cardiovascular Disease in Primary Care ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Gerald Watts

University of Western Australia, Perth (Australia)

4 More presentations in this session

Presentation thumbnail
Atrial cardiomyopathy in the electrocardiogram: the prognostic value of p-wave abnormalities in a primary care population
Doctor G. Paixao (Belo Horizonte, BR)
Abstract Slides Video
Presentation thumbnail
Using primary and routinely collected data to determine the prevalence of cardiovascular-kidney-metabolic syndrome in rural China
Professor M. Tian (Harbin, CN)
Abstract Slides Video
Presentation thumbnail
Impact of changes in serum uric acid levels on clinical outcomes in patients with asymptomatic hyperuricemia
Doctor K. Matsui (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
PCSK9 and ANGPTL3 inhibitors in homozygous familial hypercholesterolemia: a meta-analysis of randomized clinical trials
Assistant Professor I. Bytyci (Pristina, XK)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in primary care

The Event

Event poster

ESC Congress 2025

30 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
thumbnail
Congress Presentation
A randomised, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources